This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The spin-off of Retail Value has left DDR with the highest-quality assets the company has ever owned.
REG REG.PRG DDR REG.PRF ROIC RVI.WI DDR.PRJ AMZN DDR.PRK RVI DDR.PRA DDR.WI
Micro-cap REITs have lagged way behind their larger peers in June as well as year to date.
INN.PRC INN.PRB INN.PRE INN.PRD ASHFP DDR.PRJ AHT.PRI AHT.PRH AHT.PRG AHT.WI AHT.PRF DDR.PRK AHT.PRD DDR.PRA SOHOM INN.PRACL DDR SOHOL AHP.PRB SOHOB SOHO AHT.PRA RVI.WI ILPT RVI INN.PRBCL DDR.WI INN AHT INN.PRCCL
Welcome to edition 420 of Insider Weekends. Insider buying decreased last week with insiders purchasing $220.22 million of stock compared to $226.74 million in the week prior. Selling declined sharply with insiders selling $823.77 million of stock last week compared to $1.43 million in the week prior.
DDR XON RVI RVI.WI
Weingarten Realty spent a lot of time in recent quarters highlighting the discount between its valuation and what its properties were worth in the open market.
WFC WFCNP WFC.WS DDR WFC.PRL WFC.PRJ RVI.WI WFC.PRT DDR.PRJ WFC.PRR WFC.PRQ WFC.PRP WFC.PRO DDR.PRK WFC.PRN RVI DDR.PRA DDR.WI WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Between the four REIT team members, we met with over 50 REIT management teams at the June REITWeek conference.
KRC.PRG BPY KRC.PRH DCT KRC BXP TCO KRG UDR LSI TRNO EQR MAC JCAP.PRB AVB REG.PRG REG.PRF VNO EQIX TCO.PRK TCO.PRJ FR FRT JBGS RVI JCAP SPG QTS WPG PEI REG DLR.PRH DLR.PRG DLR.PRJ DLR.PRI SKT CXP EXR CONE COR ESS GGP EGP DDR MNR ROIC UE RPAI PLD SPG.PRJ KRLP OFC IRT BXP.PRB REXR DLR LPT DLR.PRC WRI DLR.PRF ESRT
DDR Corp. (DDR - Free Report) recently completed the previously-announced spin-off of a portfolio of 48 properties into a new public company — Retail Value Inc. (“RVI”). RVI will now begin regular-way trading on the NYSE under the ticker symbol of RVI. Its portfolio consists of 36 continental U.S. assets and DDR’s entire Puerto Rico portfolio of 12 assets. Per the press release of RVI, the company has a gross book value of nearly $2.
KIM.PRI DDR ABX TCO.PRK TCO.PRJ TCO KIM.PRM KIM.PRL RVI.WI KIM.PRK KIM.PRJ DDR.PRJ DDR.PRK DDR.PRA DDR.WI KIM MAC ABX
Insider buying more than doubled last week with insiders purchasing $226.74 million of stock compared to $100.92 million in the week prior. Selling, on the other hand, decreased with insiders selling $1.43 billion of stock last week compared to $1.85 million in the week prior.
DDR.PRJ DDR DDR.PRK DDR.PRA DDR.WI RVI.WI
Real estate sectors finished the week mostly higher, powered by retreating US interest rates and solid economic data. REITs climbed a half-percent while homebuilders jumped more than 1%.
DDR.PRJ ACC DDR DDR.PRK LEN HTA DDR.PRA WELL BKD DDR.WI RVI.WI
SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
DDR Corp (DDR - Free Report) has been putting in strategic efforts to revamp its portfolio through an aggressive capital-recycling program. Further, the company has made progress with the spin-off of Retail Value Inc. (RVI), as it recently announced the distribution dates for the same. This spin-off is expected to streamline the company’s portfolio. Moreover, DDR is now shifting its focus from deleveraging to redevelopment strategy aimed at retenanting and densification of the company’s properties.
KIM.PRI DDR.PRJ DDR DDR.PRK DDR.PRA KIM.PRM KIM MAC KIM.PRL KIM.PRK KIM.PRJ
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
2018-07-06 - Asif
Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...
Silicon Investor Message Boards
This table lists all message boards related to DDR / DDR Corp. on message board site Silicon Investor.
as of ET